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Fuchs  endothelial  corneal  dystrophy  (FECD)  is  a  progressive  disorder  characterized  by  corneal  endothelial
decompensation leading to corneal edema, clouding, and vision impairment. Despite improved understanding over the
last century since its first description, the exact mechanism(s) behind the pathogenesis of FECD remain unknown, and
surgical correction is the only effective treatment available. Previous studies have suggested a role for changes in aqueous
humor (AH) composition in FECD pathogenesis, so to explore this possibility, we probed the AH proteome for alterations
correlating with end-stage corneal disease. Following albumin depletion we performed label-free quantitative tandem
mass spectrometry on proteins isolated from patients with and without FECD who were scheduled to undergo routine
cataract extraction. We identified 64 proteins, most of which were identified in previous AH proteomic studies of patients
with cataracts, in the albumin-depleted fraction. The levels of five of these were significantly lower (afamin, complement
C3, histidine-rich glycoprotein, immunoglobulin heavy [IgH], and protein family with sequence similarity 3, member C
[FAM3C]), while the levels of one (suprabasin) was significantly higher in patients with FECD compared to controls
(p≤0.01). We also identified 34 proteins in the albumin-bound fraction, four of which were significantly elevated in patients
with  FECD  including  a  hemoglobin  fragment,  immunoglobulin  kappa  (IgK),  immunoglobulin  lambda  (IgL),  and
uncharacterized protein albumin (ALB), (p≤0.01). Although it has been reported that females have a greater extent of
disease than males, we were unable to detect any significant differences in protein levels due to gender. Because FECD
is a progressive disorder, regression analyses were performed to determine any significant correlations with age, and of
interest retinol-binding protein 3 was significantly correlated with age in patients with FECD (p≤0.01), whereas no proteins
in the control group correlated with age. This is the first report indicating alterations in the AH proteome with FECD, and
taken together this study suggests several novel hypotheses regarding AH proteins role in FECD pathogenesis.
Fuchs  endothelial  corneal  dystrophy  (FECD)  was
originally described by Ernst Fuchs over one hundred years
ago as a disease of the corneal epithelium; since then improved
technologies have enabled a more accurate description of the
disease  [1].  Today  it  is  recognized  as  an  adult–onset,
progressive  disorder  characterized  by  a  pleomorphic,
dysfunctional,  and  attenuated  corneal  endothelium,  and  a
thickening of Descemet’s membrane with accumulation of
focal excrescences referred to as “guttae” leading to stromal
edema and varying degrees of vision impairment [2] affecting
at least 4% of those over 40 years of age.
It has been known for several decades that evidence of
heritability is present in as many as 50% of affected patients
[3], and an increased prevalence has been reported in females
[1].  More  recently  missense  mutations  in  genes  such  as
collagen alpha-2(VIII) chain (COL8A2) have been shown to
cause  various  forms  of  corneal  endothelial  dystrophy  [4].
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Moreover,  much  work  has  been  invested  in  discovering
possible mechanisms behind sporadic FECD pathogenesis.
There is evidence that unfolded protein response, oxidative
stress, and apoptosis play a role in the onset of the disease
particularly  in  regard  to  accelerated  endothelial  cell  loss
[5-7].  Despite  the  great  strides  that  have  been  made  in
understanding FECD, the exact etiology remains unclear, and
currently  the  only  permanent  remedy  is  corneal
transplantation.  Thus,  further  investigations  into  possible
mechanisms behind FECD that potentially could lead to novel
non-invasive therapeutic approaches are warranted.
Aqueous humor supports avascular tissues in the anterior
segment of the eye such as the corneal endothelium, maintains
intraocular  pressure,  and  potentially  influences  the
pathogenesis of ocular diseases [8,9]. It has been speculated
that aqueous humor (AH) composition may play a role in
FECD [10,11], yet the precise role remains unknown. To
investigate  this  possibility,  a  necessary  first  step  is  to
determine which proteins are differentially expressed in the
AH of patients with FECD. Therefore, we performed label-
free  quantitative  mass  spectrometry  on  AH  samples  from
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2376patients with late stage FECD and patients without FECD who
were scheduled to undergo routine cataract extraction.
METHODS
Sample  collection:  Patients  were  selected  and  samples
collected as previously described [12]. Briefly, study subjects
were patients scheduled to undergo routine cataract surgery at
a tertiary referral center, Price Vision Group (Indianapolis,
IN). Exclusion criteria were as follows: previous intraocular
surgery,  history  of  conjunctivitis  or  any  ocular  infection
within the previous 3 months, intraocular inflammation, or
any eye disease other than FECD. An independent review
board (IRB) approved the study and all subjects signed a
written  Informed  Consent  document.  Before  undergoing
cataract surgery, the patient's eye was anesthetized topically
with proparacaine. A stab incision was made in the peripheral
cornea,  and  0.1  to  0.2  ml  of  anterior  chamber  fluid  was
aspirated using a 30-gauge needle. Aqueous humor samples
were stored frozen in liquid nitrogen until analysis. A single
surgeon  (F.W.P.)  collected  all  the  samples.  Any  sample
suspected of being contaminated with blood or iris pigment
was discarded. Samples from 23 subjects were analyzed (11
cataract patients and 12 patients with FECD and cataracts)
with 6 females in each group. The mean ages were 64.0±10.4
years (control group) and 62.8±8.8 year (FECD group); 22
patients  were  Caucasian  and  one  patient  with  FECD  was
African-American (Table 1).
Materials:  Acetonitrile  and  ammonium  bicarbonate  were
purchased  from  Fisher  Scientific  (Fair  Lawn,  NJ).
Dithiothreitol (DTT) and iodoacetamide (IAA) were obtained
from  Bio-Rad  Laboratories  (Hercules,  CA).  Trypsin  was
purchased  from  Promega  (Madison,  WI).  ProteoPrep
immunoaffinity depletion kit was purchased from Sigma (St.
Louis,  MO).  The  following  sample  preparation  and  mass
spectrometric  analyses  were  performed  at  METACyt
Biochemical  Analysis  Center  (Department  of  Chemistry,
Indiana University, Bloomington, IN).
Depletion  and  protein  assay:  Depletion  of  albumin  and
immunoglobulin G (IgG) was performed using ProteoPrep
immunoaffinity depletion kit as described in the instruction
manual  with  some  modification.  As  the  depletion  kit  is
designed for plasma samples and protein contents in aqueous
humor (AH) is significantly lower, preliminary studies were
performed to develop a protocol for optimal AH depletion,
which resulted in enhanced protein identification (data not
shown). Briefly, an estimate of material to be used to deplete
albumin and IgG from AH was made using a bicinchoninic
acid (BCA) protein assay and quantification of albumin and
IgG in AH samples relative to plasma assuming total protein
content of 80 µg/µl and 75% albumin and IgG in plasma. The
estimated amount of material by weight was measured from
the ProteoPrep immunoaffinity column and transferred to an
empty spin column, and depletion was performed as described
in the instruction manual.
Trypsin digestion: Protein samples were subjected to tryptic
digestion  before  analysis  as  follows:  after  thermal
denaturation at 95 °C for 5 min, samples were reduced through
the addition of DTT to a final concentration of 5 mM and
incubated at 60 °C for 45 min. Alkylation was then followed
by an addition of IAA to a final concentration of 20 mM for
45 min in the dark at room temperature. A second aliquot of
DTT was then added, increasing the final concentration of
DTT to about 10 mM. The samples were then incubated at
room  temperature  for  30  min  to  quench  the  alkylation
reaction. Next, trypsin was added (1:30 w/w) and microwave-
assisted enzymatic digestion was performed at 45 °C for 15
min at the power of 50 W using CEM Discover® System
(CEM,  Matthews,  NC).  Finally  enzymatic  digestion  was
quenched through the addition of 0.5 µl of neat formic acid.
TABLE 1. PATIENT DATA.
Normal FECD
age sex age sex
52 M 58 F
73 M 61 F
76 F 68 F
72 M 54 M
70 M 81 M
73 M 63 F
63 F 69 M
43 F 48 M
60 F 58 M
66 F 72 F
56 F 59 M
- - 62 F
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2377Instrumentation:  Liquid  chromatography  tandem  mass
spectrometry  (LC-MS/MS)  analyses  of  the  tryptic  digests
were  performed  using  a  Dionex  3000  Ultimate  nano-LC
system  (Dionex,  Sunnyvale,  CA)  interfaced  to  an  LTQ
Orbitrap hybrid mass spectrometer (Thermo Scientific, San
Jose,  CA).  Prior  to  separation,  a  4-µl  aliquot  of  trypsin
digestion  (1  µg  protein  equivalent)  was  loaded  onto  a
PepMap300 C18 cartridge (5 µm, 300 Å; Dionex) and eluted
through the analytical column (150 mm×100 µm i.d, 200 Å
pores)  packed  with  C18  magic  (Michrom  Bioresources,
Auburn, CA). Peptides originating from protein tryptic digests
were separated using a reversed-phase gradient from 10%–
55% B, 99.9% acetonitrile with 0.1% formic acid over 50 min
for proteins isolated from the aqueous humor, at 500 nl/min
flow rate and passed through an ADVANCE ionization source
(Michrom  Bioresources).  The  mass  spectrometer  was
operated  in  an  automated  data-dependent  mode  that  was
switching between MS scan and CID-MS. In this mode, eluted
LC products undergo an initial full-spectrum MS scan from
m/z 300 to 2000 in the Orbitrap at 15,000 mass resolutions,
and  subsequently  CID-MS  (at  35%  normalized  collision
energy) was performed in the ion trap. The precursor ion was
isolated using the data-dependent acquisition mode with a 2
m/z isolation width to select automatically and sequentially
five most intense ions (starting with the most intense) from
the survey scan. The total cycle (6 scans) was continuously
repeated  for  the  entire  LC-MS  run  under  data-dependent
conditions with dynamic exclusion set to 60 s. Performing MS
scanning  in  the  Orbitrap  offers  high  mass  accuracy  and
accurate charge state assignment of the selected precursor
ions.
Protein  identification  and  label-free  quantitation:  The
acquired data were searched against the International Protein
Index (IPI) human database (ipi.HUMAN.v3.69.fasta) using
SEQUEST (v. Twenty-eight rev. 12) algorithms in Bioworks
(v. 3.3). General parameters were set to: peptide tolerance 2.0
amu, fragment ion tolerance 1.0 amu, enzyme limits set as
“fully enzymatic – cleaves at both ends,” and missed cleavage
sites  set  at  2.  The  searched  peptides  and  proteins  were
validated by PeptideProphet [13] and ProteinProphet [14] in
the Trans-Proteomic Pipeline (TPP, v. 3.3.0). Only proteins
with  probability  ≥0.9000  and  peptides  with  probability
≥0.8000 were reported.
Protein quantification was performed using an in-house
software package, IdentiQuantXLTM. The retention time of
peptide for its intensity extraction was performed with an
experiment-based  algorithm  RetentionTimeXLTM  .The
intensity  of  each  validated  peptide  was  extracted  and  the
protein  quantity  was  calculated  from  peptide  intensity.
Student’s t-test was performed to determine the significance
of differences between the two group means. P-values less
than  0.01  were  considered  to  be  statistically  significant.
Linear regression analyses were performed using Spotfire®
(version 9.1.2).
RESULTS
Seeking to discover novel insights into FECD pathogenesis,
we performed label-free quantitative mass spectrometry on
AH samples derived from patients with and without FECD.
AH samples were depleted of interfering abundant proteins
such as albumin and proteins bound to albumin were eluted
in a separate fraction before LC-MSMS was used for protein
identification and quantification. Using stringent criteria for
protein identification we identified 64 proteins in the albumin-
depleted fraction (Table 2) and 34 proteins in the albumin-
bound fraction (Table 3) with high confidence. There were 6
statistically significant differentially expressed proteins in the
albumin-depleted  fraction  and  4  in  the  albumin-bound
fraction (p≤0.01); these are listed in bold in Table 2 and Table
3. The percent of the protein sequence covered by the peptides
identified with high confidence is listed for each protein along
with  the  number  of  unique  sequences,  the  coefficient  of
variation (CV), and the fold change compared to the protein
level in patients with FECD.
There  were  no  statistically  significant  differences
between  males  and  females  in  either  group  or  among  all
patients included in this study using a cut off p value of 0.01.
Using linear regression analyses, it was determined that there
were no individual proteins whose levels were significantly
associated with age in the normal group. However, at least one
protein, Retinol-binding protein 3 was positively correlated
with  age  in  the  FECD  group  (R2=0.49;  p≤0.01).  Overall,
protein levels were correlated somewhat more with age in
patients with FECD than in controls (R2=0.20 [FECD] and
0.06 [control]).
DISCUSSION
FECD causes progressive vision impairment and currently is
a  leading  indication  for  corneal  transplantation  [15].
Therefore, identification of targets for non-invasive therapy
that could slow or halt disease progression would benefit
many  patients.  In  this  study  we  sought  to  probe  the  AH
proteome for altered protein levels which correlate with end-
stage disease and could serve as novel therapeutic targets in
addition to providing insights into endothelial dysfunction
leading to FECD. AH samples provided by donor patients
with cataracts and patients with FECD and cataracts were
analyzed using a label-free quantitative mass spectrometric
approach. Protein identification was validated using Peptide-
and  Protein  Prophet  to  ensure  that  only  high  confidence
identifications were reported.
We  identified  several  protein  alterations  in  AH  with
FECD which may have important implications in the disease
process.  FECD  patients  exhibited  a  2.2  fold  decrease  in
afamin,  a  vitamin  E  binding  plasma  glycoprotein  in  the
albumin super family. Afamin deficiency has been associated
with several other chronic disorders such as atherosclerosis,
ischemic heart disease, immune deficiency, certain cancers,
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2381and neurologic syndromes with an oxidative stress component
[16]. Heiser et al. [17] previously reported in an experimental
model that afamin was protective of cortical neuronal cells
under apoptotic conditions, and a separate group reported its
production by cerebrovascular endothelial cells suggesting a
possible source in the AH [18]. FECD is characterized by
accelerated  endothelial  cell  loss,  and  several  studies  have
shown that apoptosis is increased in the corneal endothelial
cells (CEC) of patients with FECD [5,19,20]. Furthermore,
the guttae, which are characteristic of FECD, initiate in the
central cornea, the area most exposed to oxidative stress.
Therefore,  it  would  be  interesting  to  investigate  whether
patients with FECD have significant decreases in afamin in
the AH early in the disease process and whether or not that
contributes to disease by loss of a protective effect on CECs.
Furthermore,. Heiser et al. [17] also noted that Vitamin E and
afamin synergistically enhance cell survival. So it would be
interesting to investigate whether a Vitamin E deficiency in
patients with FECD could be a contributing factor as well.
We  also  found  a  2.2  fold  decrease  in  histidine-rich
glycoprotein (HRG) in the AH of patients with FECD. HRG
is a serum protein previously identified in the AH and known
to be involved in protective processes such as clearance of
apoptotic cells [21]. A decrease in such a protective effect
could contribute to disease progression in FECD patients.
Furthermore,  in  FECD  patients  we  observed  a  2.6  fold
decrease  in  complement  C3,  another  protein  involved  in
apoptotic  cell  clearance  [22],  providing  another  possible
insight  into  FECD  pathogenic  mechanisms  involving
apoptosis.  Complement  C3  is  also  known  to  be  a  key
inflammatory protein activated in Alzheimer disease. In a
transgenic  mouse  model,  it  was  shown  that  deficiency  of
complement C3 leads to accelerated amyloid beta deposition
and neurodegeneration [23]. Therefore, it would be interesting
to determine if reduced complement C3 levels in the AH of
patients with FECD also plays a role in the FECD disease
process, in which the endothelium deposits excessive amounts
of basement membrane material of abnormal composition,
resulting in guttae formation [24].
Regarding alterations in the albumin-bound fraction, it is
interesting  to  note  that  the  four  proteins  that  were
differentially  expressed  were  upregulated  by  3–6  fold  in
patients with FECD and are all common serum proteins. It is
also interesting to note that there was a 3.8 fold upregulation
of clusterin (CLU) in the albumin-bound fraction of AH in
patients with FECD (p=0.03), but there was no change in the
albumin-depleted fraction. CLU has been previously reported
as an albumin-bound protein in human plasma [25], and it is
thought to play a role in maintenance of cells at tissue-fluid
interfaces, inhibition of complement mediated cell lysis, and
protection from apoptosis [26]. Indeed, it was recently shown
that CLU attenuated oxidative stress induced apoptosis in
human CECs [27]. Jurkunas et al. [28] previously reported a
5.2 fold increase in presecretory CLU protein in CECs of
patients with FECD but no change in the mature modified
form  for  secretion  [28].  Thus,  it  is  possible  that  CLU  is
upregulated in FECD CECs as a compensatory response to
cell loss due to apoptosis but the increased secreted protein is
being sequestered by albumin thus preventing the intended
protective effect.
FECD is a progressive disorder, so we used regression
analyses to see if any particular protein was associated with
age.  We  determined  that  retinol-binding  protein  3  was
significantly  associated  with  age  in  patients  with  FECD
whereas there were no positive correlations in the control
(cataract only group). Alpha-1B-glycoprotein was also highly
associated with age among patients with FECD (R2=0.46;
p=0.015), indicating possible candidates for markers of the
disease. It is also important to note that no differences were
detected in AH proteins between men and women in this study
suggesting that gender differences in severity of FECD are not
related to the AH proteome.
Conclusions: The past one hundred years of investigation
into Fuchs endothelial corneal dystrophy (FECD) has been
marked by a dramatic improvement in our understanding of
the underpinnings of the disease at the tissue, cellular, and
molecular level. Nevertheless, no known single causal factor
has  been  discovered,  and  it  now  appears  that  it  is  a
multifactorial disease. Consistent with this line of thought, we
present here for the first time several differences in protein
concentration  that  occur  in  the  fluid  that  bathes  the
dysfunctional  tissue,  all  of  which  may  be  synergistically
contributing to the dysfunction. Several of these proteins may
be derived from serum and thus serve as a set of markers for
the disease and enable detection before a deficit in vision.
These  patients  could  then  be  candidates  for  alternative
therapies that might obviate the need for surgery later in life.
In future work, we will confirm these differentially expressed
proteins in FECD patient AH as well as test plasma samples
using  alternative  protein  quantitation  strategies  such  as
western blotting. Also, to search for biomarkers of FECD, we
will perform regression analyses seeking AH proteins whose
levels correlate strongly with the extent of FECD.
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